.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA01_Cyclophosphamide.Cyclophosphamide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA01_Cyclophosphamide.Cyclophosphamide| name: | Cyclophosphamide |
| ATC code: | L01AA01 | route: | intravenous |
| n-compartments | 2 |
Cyclophosphamide is an alkylating agent used primarily in the treatment of various cancers (such as lymphomas, leukemias, breast cancer, and ovarian cancer) and as an immunosuppressive agent for autoimmune disorders. It is approved and widely used in clinical practice today.
Population pharmacokinetics of cyclophosphamide in adult cancer patients (both male and female, age range 20-75 years) following intravenous administration.
Ismael, G, et al., & Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet. Oncology 13(9) 869–878. DOI:10.1016/S1470-2045(12)70329-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22884505
McCune, JS, et al., & Park, JR (2009). Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. Journal of clinical pharmacology 49(1) 88–102. DOI:10.1177/0091270008325928 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18927240
Batey, MA, et al., & Boddy, AV (2002). Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European journal of cancer (Oxford, England : 1990) 38(8) 1081–1089. DOI:10.1016/s0959-8049(02)00024-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12008196